ReviewTherapeutic advances in ophthalmology
Management of noninfectious scleritis.
Review in Therapeutic advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Clinical characteristics, management, and visual outcomes of presumed infectious and non-infectious anterior scleritis in a tuberculosis-endemic Indonesian Tertiary Center.International ophthalmology · 2026Article
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- Sequential ocular surgeries and multimodal immunosuppression for bilateral, medically refractory seronegative scleritis with severe peripheral corneal stromal thinning: a case report.BMC ophthalmology · 2026Article
- Long-term remission of severe refractory scleritis associated with ulcerative colitis after proctocolectomy: a case report and literature review.Clinical journal of gastroenterology · 2026Review
- Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.World journal of experimental medicine · 2025Review
- Article
- Use of cyclosporine A 0.05% ophthalmic emulsion for a distinctive intrapalpebral phenotype of anterior scleritis.BMJ case reports · 2025Article
- Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies.Biomedicines · 2024Review
- Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Management of Scleritis in Older Adults.Drugs & aging · 2024Article
- Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies.Journal of ophthalmic inflammation and infection · 2024Article
- Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators.Life (Basel, Switzerland) · 2024Review
- Scleritis following intravitreal brolucizumab injection: a case series.Journal of medical case reports · 2024Article
- Unveiling Ocular Manifestations in Systemic Lupus Erythematosus.Journal of clinical medicine · 2024Review
- Review
- Diagnosis and Treatment of Central Serous Chorioretinopathy in Patients with Scleritis.Medicina (Kaunas, Lithuania) · 2023Article
- A rare case of scleritis and multiple rheumatoid pulmonary nodules associated with seronegative rheumatoid arthritis.Oxford medical case reports · 2023Article
- Clinical spectrum and management of anterior scleritis: case reports.Therapeutic advances in ophthalmologyArticle
- Intraocular pressure changes after posterior sub-Tenon injection of triamcinolone acetonide in a sample of Iraqi patients with noninfectious uveitis.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Scleritis is a manifestation of inflammatory eye disease that involves the sclera. It can be divided into multiple subtypes, including diffuse anterior, nodular anterior, necrotizing, and posterior scleritis. In many cases, scleritis is restricted to the eye; however, it can occur in the context of systemic illness, particularly autoimmune and infectious conditions. Patients with autoimmune conditions, such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, and polyangiitis with granulomatosis, may develop scleritis flares that may require topical and systemic therapy. Initial therapy typically involves oral nonsteroidal anti-inflammatory drugs (NSAIDs); however, it is important to address the underlying condition, particularly if systemic. Other treatment regimens typically involve either local or systemic steroids or the use of immunomodulatory agents, which have a wide range of efficacy and documented use in the literature. There is a myriad of immunomodulatory agents used in the treatment of scleritis including antimetabolites, calcineurin inhibitors, biologics, and alkylating agents. In this review, we highlight the various subtypes of noninfectious scleritis and explore each of the mainstay agents used in the management of this entity. We explore the use of steroids and NSAIDs in detail and discuss evidence for various immunomodulatory agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.